PathAI
PathAI is dedicated to improving patient outcomes through reliable AI-powered pathology technology and collaboration with biopharma and pathology laboratories. They develop comprehensive precision pathology solutions, leveraging data from over 15 million annotations and a network of over 450 pathologists, to accelerate drug development, improve diagnostic accuracy, and facilitate life-saving therapies. Their mission is to transform pathology with AI models that support research, clinical trials, and diagnostic use, aiming for more accurate diagnoses, better treatment matching, and increased drug approvals.
Industries
Nr. of Employees
medium (51-250)
PathAI
Patents
Systems and methods for training a statistical model to predict tissue characteristics for a pathology image
US-12597523-B1
View DetailsSystems and methods for training a model to predict survival time for a patient
US-12073948-B1
View DetailsSystems and methods for training a statistical model to predict tissue characteristics for a pathology image
US-11908139-B1
View DetailsSystems and methods for training a statistical model to predict tissue characteristics for a pathology image
US-11756198-B1
View Details
Systems and methods for training a statistical model to predict tissue characteristics for a pathology image
US-12597523-B1
View DetailsSystems and methods for training a model to predict survival time for a patient
US-12073948-B1
View DetailsSystems and methods for training a statistical model to predict tissue characteristics for a pathology image
US-11908139-B1
View DetailsSystems and methods for training a statistical model to predict tissue characteristics for a pathology image
US-11756198-B1
View DetailsProducts
Digital pathology image management system
Cloud-native enterprise image management and workflow platform that hosts whole-slide images, manages cases, and deploys AI analytics for research and clinical use.
AI-based biomarker and histology feature panels
Pre-built and custom AI panels for quantifying biomarkers (e.g., HER2, ER, PR, Ki-67, PD-L1) and extracting spatial histopathology features for oncology, NASH/MASH, and IBD research.
Validated disease-specific AI scoring assays
Research-use AI assays that output standardized scores and metrics (for example: PD-L1 percent positive, HER2 scores, Ki-67 percent positive, and histologic index conversions for ulcerative colitis).
Digital pathology image management system
Cloud-native enterprise image management and workflow platform that hosts whole-slide images, manages cases, and deploys AI analytics for research and clinical use.
AI-based biomarker and histology feature panels
Pre-built and custom AI panels for quantifying biomarkers (e.g., HER2, ER, PR, Ki-67, PD-L1) and extracting spatial histopathology features for oncology, NASH/MASH, and IBD research.
Validated disease-specific AI scoring assays
Research-use AI assays that output standardized scores and metrics (for example: PD-L1 percent positive, HER2 scores, Ki-67 percent positive, and histologic index conversions for ulcerative colitis).
Services
AI-powered biomarker discovery, spatial histopathology feature extraction, and custom algorithm development to support translational research across oncology, liver disease, and inflammatory bowel disease.
End-to-end support for clinical trials including regulated prospective algorithm development, core pathology operations, expert manual review, and pathology protocol strategy.
Coordinated design, development, and validation services for software-as-a-medical-device and companion diagnostics, including regulatory and market access strategy.
Licensing of quantitative histopathology data products linked to structured clinical and molecular datasets for biomarker discovery and validation.
Regulated laboratory operations providing sample receipt, processing, staining (H&E, IHC, special stains), multiplex assays, slide scanning, storage, and slide-level scoring.
AI-powered biomarker discovery, spatial histopathology feature extraction, and custom algorithm development to support translational research across oncology, liver disease, and inflammatory bowel disease.
End-to-end support for clinical trials including regulated prospective algorithm development, core pathology operations, expert manual review, and pathology protocol strategy.
Coordinated design, development, and validation services for software-as-a-medical-device and companion diagnostics, including regulatory and market access strategy.
Licensing of quantitative histopathology data products linked to structured clinical and molecular datasets for biomarker discovery and validation.
Regulated laboratory operations providing sample receipt, processing, staining (H&E, IHC, special stains), multiplex assays, slide scanning, storage, and slide-level scoring.
Expertise Areas
- Digital pathology and image management
- AI-driven biomarker quantification and spatial analysis
- Clinical trial pathology services
- Assay development and validation for tissue-based methods
Key Technologies
- Whole-slide imaging (WSI)
- Deep learning for histopathology
- Graph neural networks (GNNs)
- Multiple instance learning (MIL)
News & Updates
2022 FDA 510(k) Clearance for AISight Dx
PathAI received FDA 510(k) clearance and CE Mark for its digital pathology platform, AISight Dx, for primary diagnosis in clinical settings.
2024 Strategic Partnership with Quest Diagnostics
Partnership involving sale of PathAI Diagnostics and licensing of AISight platform.
PathAI Founded in 2016
Established to apply technology to pathology to reduce error rates and increase accuracy.
PathAI's Certifications in 2019
Received ISO 13485, ISO 27001, and MDSAP certifications validating its approach to medical device software and information security.
PathAI's First Patents in 2020
Patents for predicting patient survival time and tissue characteristics from pathology images.
Series C Funding in 2021
Raised $165 million to expand research and development capabilities.
2022 FDA 510(k) Clearance for AISight Dx
PathAI received FDA 510(k) clearance and CE Mark for its digital pathology platform, AISight Dx, for primary diagnosis in clinical settings.
2024 Strategic Partnership with Quest Diagnostics
Partnership involving sale of PathAI Diagnostics and licensing of AISight platform.
PathAI Founded in 2016
Established to apply technology to pathology to reduce error rates and increase accuracy.
PathAI's Certifications in 2019
Received ISO 13485, ISO 27001, and MDSAP certifications validating its approach to medical device software and information security.
PathAI's First Patents in 2020
Patents for predicting patient survival time and tissue characteristics from pathology images.
Series C Funding in 2021
Raised $165 million to expand research and development capabilities.